M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice.

@article{Fisher1998M1MA,
  title={M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice.},
  author={Abraham Fisher and Rachel McCulloch Brandeis and Stephen Chapman and Zipora Pittel and Daniel M. Michaelson},
  journal={Journal of neurochemistry},
  year={1998},
  volume={70 5},
  pages={1991-7}
}
Recent studies suggest that apolipoprotein E (apoE) plays a specific role in brain cholinergic function and that the E4 allele of apoE (apoE4), a major risk factor for Alzheimer's disease (AD), may predict the extent of cholinergic dysfunction and the efficacy of cholinergic therapy in this disease. Animal model studies relevant to this hypothesis revealed that apoE-deficient (knockout) mice have working memory impairments that are associated with distinct dysfunction of basal forebrain… CONTINUE READING